EA200601043A1 - Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара - Google Patents

Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара

Info

Publication number
EA200601043A1
EA200601043A1 EA200601043A EA200601043A EA200601043A1 EA 200601043 A1 EA200601043 A1 EA 200601043A1 EA 200601043 A EA200601043 A EA 200601043A EA 200601043 A EA200601043 A EA 200601043A EA 200601043 A1 EA200601043 A1 EA 200601043A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
expression
promoters
modified
ovipacaxi
Prior art date
Application number
EA200601043A
Other languages
English (en)
Other versions
EA012846B1 (ru
Inventor
Соня Лейрер
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA200601043A1 publication Critical patent/EA200601043A1/ru
Publication of EA012846B1 publication Critical patent/EA012846B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Настоящее изобретение относится к промоторам, в частности к экспрессии генов и/или кодирующих последовательностей вирусов осповакцины, таких как модифицированный вирус осповакцины штамма Анкара (MVA). Кроме того, настоящее изобретение относится к экспрессионным кассетам, содержащим указанный промотор, векторы, содержащие указанные экспрессионные кассеты, а также к фармацевтическим композициям и вакцинам.
EA200601043A 2003-11-24 2004-10-27 Промотор для экспрессии генов в вирусах осповакцины и/или в клетках, инфицированных вирусом осповакцины, и способы его применения EA012846B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24
EP04000943A EP1536015B1 (en) 2003-11-24 2004-01-17 Promoters for expression in modified vaccinia virus ankara
PCT/EP2004/012125 WO2005054484A1 (en) 2003-11-24 2004-10-27 Promoters for expression in modified vaccinia virus ankara

Publications (2)

Publication Number Publication Date
EA200601043A1 true EA200601043A1 (ru) 2006-10-27
EA012846B1 EA012846B1 (ru) 2009-12-30

Family

ID=34442836

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601043A EA012846B1 (ru) 2003-11-24 2004-10-27 Промотор для экспрессии генов в вирусах осповакцины и/или в клетках, инфицированных вирусом осповакцины, и способы его применения

Country Status (18)

Country Link
US (3) US7816508B2 (ru)
EP (4) EP1536015B1 (ru)
JP (2) JP2007512009A (ru)
KR (1) KR20060109873A (ru)
CN (1) CN1898390A (ru)
AT (4) ATE377088T1 (ru)
AU (1) AU2004295382A1 (ru)
BR (1) BRPI0416916A (ru)
CA (1) CA2546680A1 (ru)
DE (4) DE602004009743T2 (ru)
DK (3) DK1845164T3 (ru)
EA (1) EA012846B1 (ru)
IL (4) IL174653A0 (ru)
NO (1) NO20062948L (ru)
NZ (1) NZ547405A (ru)
SG (2) SG142300A1 (ru)
UA (1) UA90098C2 (ru)
WO (1) WO2005054484A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2256323T5 (es) * 2000-11-23 2016-11-21 Bavarian Nordic A/S Variante del virus Vaccinia Ankara Modificado
EP1536015B1 (en) * 2003-11-24 2007-10-31 Bavarian Nordic A/S Promoters for expression in modified vaccinia virus ankara
EP2042604A1 (en) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV promoter driven overexpression of recombinant antigens
CA2741724C (en) * 2008-11-27 2016-10-04 Bavarian Nordic A/S Promoters for recombinant viral expression
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
EP2627774B1 (en) 2010-10-15 2018-11-21 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) influenza vaccine
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
WO2018209315A1 (en) * 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
DE60113512T2 (de) 2000-03-14 2006-06-22 Bavarian Nordic A/S Veränderter stamm des modifizierten vaccinia-virus ankara (mva)
ES2256323T5 (es) * 2000-11-23 2016-11-21 Bavarian Nordic A/S Variante del virus Vaccinia Ankara Modificado
ES2334335T3 (es) * 2001-03-08 2010-03-09 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Mva que expresa genes de envoltura, gag y pol de vih modificados.
SI1404852T1 (sl) 2002-05-16 2006-04-30 Bavarian Nordic As Ekspresija genov v modularnem vakcinija virusa Ankara z uporabo ATI promotorja kravjih ospic
CA2489301A1 (en) * 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
EP1536015B1 (en) * 2003-11-24 2007-10-31 Bavarian Nordic A/S Promoters for expression in modified vaccinia virus ankara

Also Published As

Publication number Publication date
KR20060109873A (ko) 2006-10-23
DE602004018975D1 (de) 2009-02-26
IL199127A (en) 2010-12-30
CA2546680A1 (en) 2005-06-16
NO20062948L (no) 2006-08-23
EP1536015B1 (en) 2007-10-31
BRPI0416916A (pt) 2007-01-23
JP2011067219A (ja) 2011-04-07
DE602004009743D1 (de) 2007-12-13
EA012846B1 (ru) 2009-12-30
ATE420191T1 (de) 2009-01-15
EP1956094B1 (en) 2011-04-06
EP1956094A1 (en) 2008-08-13
DE602004027767D1 (de) 2010-07-29
DE602004009743T2 (de) 2008-08-28
IL199126A (en) 2010-12-30
EP1689872A1 (en) 2006-08-16
EP1689872B1 (en) 2009-01-07
DK1689872T3 (da) 2009-04-27
SG169325A1 (en) 2011-03-30
DK1536015T3 (da) 2008-02-18
NZ547405A (en) 2008-06-30
UA90098C2 (en) 2010-04-12
EP1845164A2 (en) 2007-10-17
EP1845164B1 (en) 2010-06-16
WO2005054484A1 (en) 2005-06-16
EP1536015A1 (en) 2005-06-01
ATE471383T1 (de) 2010-07-15
US7816508B2 (en) 2010-10-19
IL199128A (en) 2011-03-31
SG142300A1 (en) 2008-05-28
ATE377088T1 (de) 2007-11-15
US20110014242A1 (en) 2011-01-20
EP1845164A3 (en) 2008-03-19
US20080112971A1 (en) 2008-05-15
US20110008792A1 (en) 2011-01-13
DE602004032187D1 (de) 2011-05-19
IL174653A0 (en) 2006-08-20
CN1898390A (zh) 2007-01-17
AU2004295382A1 (en) 2005-06-16
JP2007512009A (ja) 2007-05-17
DK1845164T3 (da) 2010-09-20
ATE504654T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
ATE497785T1 (de) Sequenzielle freisetzung immunogener moleküle über adenoviren und adeno-assoziierte viren vermittelte abgaben
HK1100121A1 (en) Malaria prime/boost vaccines
DK1618128T3 (da) Tuberkulosevaccine med forbedret effektivitet
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
MXPA05005549A (es) Virus recombinante de viruela que comprende al menos dos promotores ati de viruela de vaca.
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
ATE532861T1 (de) Expressionsvektor
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
ATE493146T1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase
WO2005001096A8 (fr) Vaccins contre le sras

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU